ReviewJACC. CardioOncology2022
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:
Review in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.Journal of cardiovascular development and disease · 2026Review
- Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways with AI-Assisted Literature Clustering.International journal of molecular sciences · 2026Review
- Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.Journal of the American Heart Association · 2026Article
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.Journal for immunotherapy of cancer · 2026Article
- Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review.The Lancet. Oncology · 2026Article
- Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Immune checkpoint inhibitors and myocardial infarction.Journal of thrombosis and thrombolysis · 2026Review
- Caught in the crossfire: cardiac complications of cancer therapy.The Journal of clinical investigation · 2026Review
- Immunotherapy-related cardiovascular toxicity: from mechanisms to management.Frontiers in pharmacology · 2026Review
- Feasibility of [Diagnostics (Basel, Switzerland) · 2025Article
- CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.Cardiovascular research · 2025Article
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore.International journal of molecular sciences · 2025Review
- Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.EClinicalMedicine · 2025Article
- Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology.Cancers · 2025Review
- Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease.European journal of medical research · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging evidence supports the association between ICI therapy with accelerated atherosclerosis and atherosclerotic cardiovascular (CV) events. We discuss the biological plausibility and the clinical evidence supporting an effect of inhibition of these immune checkpoints on atherosclerotic CV disease. Further, we provide a perspective on potential diagnostic and pharmacological strategies to reduce atherosclerotic risk in ICI-treated patients. Our understanding of the pathophysiology of ICI-related atherosclerosis is in its early stages. Further research is needed to identify the mechanisms linking ICI therapy to atherosclerosis, leverage the insight that ICI therapy provides into CV biology, and develop robust approaches to manage the expanding cohort of patients who may be at risk for atherosclerotic CV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.